Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Aurealis Therapeutics

## Sitemaps
[XML Sitemap](https://aurealistherapeutics.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Aurealis Therapeutics to Attend Swiss Biotech Day 2025](https://aurealistherapeutics.com/aurealis-news/swissbiotechday2025/): Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, announced today that Chief Operating Officer Laurent Décory will attend Swiss Biotech Day 2025, taking place in Basel, Switzerland, from 5-6 May.
- [Aurealis Therapeutics Appoints Hanna P. Lesch, PhD, as Chief Technology Officer](https://aurealistherapeutics.com/aurealis-news/aurealis-therapeutics-appoints-hanna-lesch-as-cto/): Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, is proud to announce the appointment of Hanna P. Lesch, PhD, as Chief Technology Officer (CTO). Dr. Lesch brings over two decades of world-class expertise in gene and cell therapy manufacturing, viral vector technologies, mRNA platforms, and the scaling of complex manufacturing processes from discovery towards the commercial launch.
- [Aurealis Therapeutics Concludes Largest EWMA Participation to Date with Exciting Investigator Data of DIAMEND Phase 2 DFU Clinical Trial Presented by Prof. Alberto Piaggesi](https://aurealistherapeutics.com/aurealis-news/ewma2025/): Update — May 2026 The final blinded evaluator results have since been confirmed. See the DIAMEND Phase 2 results.
- [Aurealis Therapeutics Raises CHF 8 Million to Complete Phase 2 Clinical Studies in Chronic Wounds and Accelerate Oncology Program](https://aurealistherapeutics.com/aurealis-news/aurealis-financing2024/): Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, has raised CHF 8 million from existing investors and shareholders.
- [Aurealis Therapeutics Announces Peer-Reviewed Paper Published from Phase 1 Study of AUP-16 for Non-Healing Diabetic Foot Ulcers](https://aurealistherapeutics.com/aurealis-news/aup-16-dfu-phase1-resultspublished/): Update — May 2026 The AUP-16 Phase 1 DFU clinical study was followed by the DIAMEND Phase 2 clinical trial, which has since been completed. See the DIAMEND Phase 2 results.
- [Aurealis Therapeutics Announces Positive Blinded Evaluator Efficacy Results of “DIAMEND” Phase-2 Randomized Controlled Trial: AUP-16 Tripling the Complete Wound Closure Rate in Patients with Chronic Diabetic Foot Ulcers](https://aurealistherapeutics.com/aurealis-news/aup-16-diamend-dfu-phase2-results/): Aurealis Therapeutics, a clinical-stage company developing scalable and low COGS multi-target cell and gene therapies for chronic wounds and cancer, today announced positive blinded evaluator efficacy results and completion of the Database Lock (DBL) in its DIAMEND Phase 2 clinical trial of AUP-16, the company’s lead asset for the treatment of non-healing neuro-ischemic Diabetic Foot Ulcers (DFUs). AUP-16 received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) in February 2024 for its potential to address the significant unmet medical need of chronic DFUs.
- [Aurealis Therapeutics Announces Last Patient Last Treatment in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16](https://aurealistherapeutics.com/aurealis-news/aup-16-dfu-phase2-lplt/): Update — May 2026 The DIAMEND AUP-16 Phase 2 DFU clinical study has since been completed. See the DIAMEND Phase 2 results.
- [Aurealis Therapeutics Proudly Sponsors EWMA Diabetic Foot Committee](https://aurealistherapeutics.com/aurealis-news/ema-dfc/): Aurealis Therapeutics is pleased to announce our sponsorship of the newly established EWMA Diabetic Foot Committee, an initiative launched by the European Wound Management Association (EWMA) in 2023. This committee is dedicated to improving the management and care of diabetic foot ulcers (DFUs) across Europe by implementing an International Working Group on the Diabetic Foot (IWGDF) guidelines and promoting increased research in this relevant area.
- [Aurealis Therapeutics Completes Patient Recruitment in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16](https://aurealistherapeutics.com/aurealis-news/aup-16-dfu-phase2-patientrecruitmentcompleted/): Update — May 2026 The DIAMEND AUP-16 Phase 2 DFU clinical study has since been completed. See the DIAMEND Phase 2 results.
- [Interview with Laurent Décory COO at Aurealis Therapeutics | Career journey, AUP-16 advancements and global partnerships](https://aurealistherapeutics.com/aurealis-news/laurent-decory-team-interviews/): Watch the video interview on YouTube
- [Aurealis Therapeutics Enhances Board of Directors Expertise by Appointing Tuomo Pätsi as New Member](https://aurealistherapeutics.com/aurealis-news/tuomo-patsi-newbodmember/): Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, is pleased to announce the appointment of Tuomo Pätsi as a new member of its Board of Directors. Mr. Pätsi’s election was confirmed on June 18, 2024 during Aurealis Therapeutics’ Annual General Meeting. Existing Board Directors Silvio Inderbitzin, Jean de Gunzburg, Juha Yrjänheikki and Laurent Décory were elected to continue along with Roger Meier as the Chairman of the Board.
- [Aurealis Therapeutics Concludes Successful Partnering Week in China](https://aurealistherapeutics.com/aurealis-news/partneringweekinchina2024/): Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced the successful completion of its partnering visit to China from 13-17 May, 2024.
- [Interview with Hanna-Riikka Kärkkäinen Head of Quality and Regulatory Affairs at Aurealis Therapeutics |  Professional career, AUP-16 PRIME designation, FDA Advice & more](https://aurealistherapeutics.com/aurealis-news/hanna-riikka-team-interviews/): Watch the video interview on YouTube
- [Half of the Patients Successfully Recruited and Randomized in Aurealis Therapeutics DIAMEND AUP-16 Phase-2 Study](https://aurealistherapeutics.com/aurealis-news/aup-16-dfu-phase2-30patientsrecruited/): Update — May 2026 The DIAMEND AUP-16 Phase 2 DFU clinical study has since been completed. See the DIAMEND Phase 2 results.
- [Aurealis Therapeutics Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support and Accelerated Assessment of AUP-16 in Non-healing Diabetic Foot Ulcers](https://aurealistherapeutics.com/aurealis-news/aup16-prime-nhdfu/): Update — May 2026 The AUP-16 DFU Phase 1 results have since been published in Therapeutic Advances in Endocrinology and Metabolism and the DIAMEND Phase 2 trial has since been completed. See the peer-reviewed Phase 1 paper, the Phase 1 results publication, and the DIAMEND Phase 2 results.
- [Interview with Haritha Samaranayake CMO of Aurealis Therapeutics | Professional journey, AUP-16 clinical trials in DFU & development plans for oncology](https://aurealistherapeutics.com/aurealis-news/haritha-samaranayake-team-interviews/): Watch full interview on YouTube
- [AUP-16: More cost-effective than the current Standard Of Care at healing Diabetic Foot Ulcers revealed at ISPOR Europe 2023](https://aurealistherapeutics.com/aurealis-news/aurealis-isporeurope2023/): Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, participated in ISPOR Europe Health Economics and Market Access conference held from 12-15 November in Copenhagen, Denmark. During this conference, Laurent Décory, COO of Aurealis Therapeutics, presented one of the company’s latest developments: a detailed Markov model used to determine the cost-effectiveness of AUP-16 at healing Diabetic Foot Ulcers (DFUs) when compared to the current Standard of Care (SOC).
- [Aurealis Therapeutics launches Venous Leg Ulcer (VLU) scientific expert group, an important step towards AUP-16 VLU phase 2 clinical trial](https://aurealistherapeutics.com/aurealis-news/vlu-scientificexpertgroup/): Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, announces the initiation of its Venous Leg Ulcer (VLU) scientific expert group. This initiative is an important step towards the planning and execution of the Phase 2 clinical trial of AUP-16 for Venous Leg Ulcers (VLUs).
- [Aurealis Therapeutics announces first patient dosed in DIAMEND Phase 2 Diabetic Foot Ulcer clinical trial of AUP-16](https://aurealistherapeutics.com/aurealis-news/aup-16-phase2-dfu-firstpatient/): Update — May 2026 The DIAMEND AUP-16 Phase 2 DFU clinical study has since been completed. See the DIAMEND Phase 2 results.
- [Aurealis Therapeutics presented advancements in multi-target bacterial gene therapies at the 14th International Symposium on Lactic Acid Bacteria](https://aurealistherapeutics.com/aurealis-news/labsymposium23/): Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, is making remarkable advances in the field with its 4-in-1 technology platform. Director of Genetic Engineering & Manufacturing, Igor Mierau, showcased the company's research and results at the 14th International Symposium on Lactic Acid Bacteria, held from August 27-31 at Hotel Zuiderduin in Egmond aan Zee, the Netherlands.
- [Aurealis Therapeutics shines in Nordic Life Science News with in-depth interview on gene therapy innovations](https://aurealistherapeutics.com/aurealis-news/nlsn-23/): Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, is excited to share its recent feature in the well-known life science journal, Nordic Life Science News. The article titled “From Theory to Therapy: Gene Therapy” has shared remarkable insights from an interview with Laurent Décory, COO of Aurealis Therapeutics.
- [Aurealis Therapeutics strengthens its Board of Directors by appointing Jean de Gunzburg as a new member](https://aurealistherapeutics.com/aurealis-news/jean-de-gunzburg-newbodmember/): Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer, announced today that Jean de Gunzburg, Scientist and Investor, Founder and Chairman of Zagdanut Ltd, Director of Cardiawave SA, previously CSO and Director of Da Volterra, and Founder and Chairman of Metsya Ltd, has been appointed as a new member of the company’s Board of Directors, effective June 14, 2023. Existing Board Directors Silvio Inderbitzin, Juha Yrjänheikki and Laurent Décory were elected to continue along with Roger Meier as the Chairman of the Board.
- [Aurealis Therapeutics accelerates oncology program: First abstract published at ASCO as the team prepares for Annual Meeting in Chicago](https://aurealistherapeutics.com/aurealis-news/aurealis-asco-abstract-2023/): Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, accelerates its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55. The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has been accepted and published on the prestigious American Society of Clinical Oncology (ASCO) website.
- [Aurealis Therapeutics announces approval of multi-center, randomized, placebo-controlled diabetic foot ulcer Phase 2 study to start May 2023 in Italy, Germany and Poland.](https://aurealistherapeutics.com/aurealis-news/aup-16-phase2-dfu-applicationapproval/): Update — May 2026 The DIAMEND AUP-16 Phase 2 DFU clinical study has since been completed. See the DIAMEND Phase 2 results.
- [Aurealis Therapeutics will be presenting during the European Wound Management Association (EWMA) 2023 Conference](https://aurealistherapeutics.com/aurealis-news/aurealis-therapeutics-ewma-2023/): Aurealis Therapeutics is excited to sponsor the European Wound Management Association (EWMA) 2023 Conference taking place in Milan, Italy from 3-5 May 2023. Our CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake and will be attending the conference.
- [Aurealis Therapeutics is attending the Swiss Biotech Day 2023](https://aurealistherapeutics.com/aurealis-news/aurealis-swissbiotechday2023/): Juha Yrjänheikki (CEO) and Laurent Décory (COO) will be attending the Swiss Biotech Day 2023 which will take place from 24-25 April in Basel, Switzerland. This will be a fantastic opportunity to meet investors and discuss potential partnerships with pharma companies.
- [Aurealis Therapeutics raises $10 Million in an oversubscribed Series A financing to accelerate Phase 2 clinical studies in chronic wounds and preclinical development in oncology with its first-in-class technology platform](https://aurealistherapeutics.com/aurealis-news/10-million-series-a-funding/): Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish Industry Investment Ltd) with participation of Huahai Pharmaceuticals, family offices and biotech HNWIs.
- [Aurealis Therapeutics completes Phase 1 Last Patient Last Visit: After 12 months follow-up, no healed ulcer has recurred](https://aurealistherapeutics.com/aurealis-news/phase-1-dfu-lastpatientlastvisit/): Update — May 2026 The AUP-16 Phase 1 DFU clinical study results have since been published in Therapeutic Advances in Endocrinology and Metabolism. See the Phase 1 results publication and the peer-reviewed paper in Therapeutic Advances in Endocrinology and Metabolism.
- [Aurealis Therapeutics successfully completes treatment period of its AUP-16 Phase 1 study in non-healing Diabetic Foot Ulcers: 83% patients receiving lead therapeutic dose achieved complete healing](https://aurealistherapeutics.com/aurealis-news/aup-16-phase-1-study-completed/): Update — May 2026 The AUP-16 Phase 1 DFU clinical study has since been completed. See the Phase 1 results publication and the peer-reviewed paper in Therapeutic Advances in Endocrinology and Metabolism.
- [Aurealis Therapeutics publishes first study on four-in-one -combination therapy using live lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds](https://aurealistherapeutics.com/aurealis-news/aurealis-first-study-plosone/): Update — May 2026 AUP-16 has since completed Phase 1 and Phase 2 DFU clinical trials. See the Phase 1 results publication, the peer-reviewed Phase 1 paper in Therapeutic Advances in Endocrinology and Metabolism, and the DIAMEND Phase 2 study results.
- [Aurealis Therapeutics to strengthen its Management Team by appointing Laurent Décory as Chief Operating Officer](https://aurealistherapeutics.com/aurealis-news/laurent-decory-managementteam/): Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. Laurent will be in charge of Business Development, Health Economics, Marketing & Communication and Scientific Advisory activities. The timing of the nomination of Dr. Décory occurs in parallel with the company successfully completing an exclusive license and collaboration agreement with XBiome, for the clinical development and commercialization of AUP-16, Aurealis investigational therapy for Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory diseases, in greater China.
- [Aurealis Therapeutics Partner Xbiome Receives IND Approval from China’s National Medical Products Administration for the Phase 2 Study with AUP-16 in Diabetic Foot Ulcers](https://aurealistherapeutics.com/aurealis-news/xbiome-phase2approval-aup-16/): Xbiome announced that its Phase 2 study with AUP-16 (AUP1602-C) in Diabetic Foot Ulcer (DFU) has officially obtained IND approval from the National Medical Products Administration (NMPA) and the study can be initiated in China.
- [Aurealis Therapeutics and Xbiome enter into a license and collaboration agreement for Aurealis four-in-one diabetic foot ulcer and inflammatory disease cell and gene therapy AUP-16 in Greater China](https://aurealistherapeutics.com/aurealis-news/aurealis-xbiome-licenseagreement/): Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. Shanghai-based Lynx Financial served as Aurealis’ exclusive financial advisor in this transaction.
- [Aurealis Therapeutics successfully completes low therapeutic dose cohort of AUP-16 Phase 1 DFU trial, advances to medium therapeutic dose group](https://aurealistherapeutics.com/aurealis-news/aup-16-dfu-phase1-lowdosegroupcompleted/): Update — May 2026 The AUP-16 Phase 1 DFU clinical study has since been completed. See the Phase 1 results publication and the peer-reviewed paper in Therapeutic Advances in Endocrinology and Metabolism.
- [Aurealis Therapeutics novel chronic wound treatment to be presented at the 4th Experts Meeting on Microbiome & Skin Health and Disease 2020](https://aurealistherapeutics.com/aurealis-news/expertsmeetingmicrobiome/): Haritha Samaranayake, MD, PhD, Medical Director of Aurealis Therapeutics will give a talk about development of AUP-16, the company´s lead product for non-healing wounds such as diabetic foot ulcer. The presentation is titled “Development of a Live Biotherapeutic to treat diabetic foot ulcer“ and is scheduled for Tuesday, December 15th, 2020 at 14:30 CET.
- [Aurealis Therapeutics has initiated repeated dosing groups in the AUP-16 Phase 1 Diabetic Foot Ulcer clinical trial](https://aurealistherapeutics.com/aurealis-news/aup-16-dfu-phase1-repeateddosinggroups/): Update — May 2026 The AUP-16 Phase 1 DFU clinical study has since been completed. See the Phase 1 results publication and the peer-reviewed paper in Therapeutic Advances in Endocrinology and Metabolism.
- [Aurealis Therapeutics to strengthen its Board of Directors by appointing Laurent Décory](https://aurealistherapeutics.com/aurealis-news/laurent-decory-newbodmember/): Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the four-in-one biologic drug for chronic non-healing wounds and regenerative diseases, announced today that Mr. Laurent Décory has joined the Board of Directors of the company as of June 10th, 2020. Existing Board Directors Iain Buchanan, Silvio Inderbitzin and Roger Meier were elected to continue along with CEO Juha Yrjänheikki joining the Board. The timing of the nomination of Dr. Décory occurs in parallel with the company successfully completing the first safety cohort in the phase 1-2A diabetic foot ulcer clinical trial and advancing to repeated dosing cohorts.
- [Aurealis Therapeutics pioneering multiple drug producing bacteria AUP-16 dosed to the first diabetic foot ulcer patient in the Phase 1-2A trial](https://aurealistherapeutics.com/aurealis-news/aup-16-dfu-phase1-firstpatient/): Update — May 2026 The AUP-16 Phase 1 DFU clinical study has since been completed. See the Phase 1 results publication and the peer-reviewed paper in Therapeutic Advances in Endocrinology and Metabolism.
- [Aurealis Therapeutics receives Clinical Trial Application approval for AUP-16 Phase 1 DFU study](https://aurealistherapeutics.com/aurealis-news/aup-16-dfu-phase1-ctaapproved/): Update — May 2026 The AUP-16 Phase 1 DFU clinical study has since been completed. See the Phase 1 results publication and the peer-reviewed paper in Therapeutic Advances in Endocrinology and Metabolism.
- [Aurealis Therapeutics announces 7.8MCHF financing to advance lead candidate AUP-16 for diabetic foot ulcers under new brand: Aurealis Therapeutics AG](https://aurealistherapeutics.com/aurealis-news/aurealis-financing2019/): Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The company also confirmed the de-merger and a plan to develop and commercialize the AUP-16 under a new legal entity – Aurealis Therapeutics AG. Prior to this announcement, Aurealis Therapeutics was Aurealis Pharma AG; the de-merger separated Aurealis Pharma AG from the newly created Aurealis Therapeutics AG. The proceeds of this financing will be used in Aurealis Therapeutics AG to fund the AUP-16 first-in-human Phase 1 clinical study for diabetic foot ulcers (DFUs).
- [Aurealis Therapeutics submits Clinical Trial Application for AUP-16 Phase 1 DFU study](https://aurealistherapeutics.com/aurealis-news/aup-16-dfu-phase1-cta/): Update — May 2026 The AUP-16 Phase 1 DFU clinical study has since been completed. See the Phase 1 results publication and the peer-reviewed paper in Therapeutic Advances in Endocrinology and Metabolism.
- [Aurealis Therapeutics to strengthen its Board of Directors by appointing Iain Buchanan](https://aurealistherapeutics.com/aurealis-news/iain-buchanan-newbodmember/): Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that Mr. Iain Buchanan has joined the board of directors of the company as of May 16th 2018. Existing board members CSO and founder Mr. Thomas Wirth, senior life science executive, Mrs. Nora Kaarela, senior pharma industry and board professional and investor Mr. Silvio Inderbitzin, and early stage life sciences board professional and start-up and growth company enabler Mr. Roger Meier were duly elected to continue as board directors.
- [Aurealis Therapeutics to present at the European Wound Management Association (EWMA) Congress 2018](https://aurealistherapeutics.com/aurealis-news/aurealis-ewma2018/): Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company's progress and clinical development plans for lead development product AUP-16 indicated for chronic wounds at the European Wound Management Association (EWMA) Congress in Krakow, Poland on 9th – 11th May, 2018.
- [Aurealis Therapeutics to attend the Swiss Biotech Day 2018](https://aurealistherapeutics.com/aurealis-news/aurealis-swissbiotechday2018/): Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company's progress at the Swiss Biotech Day in Basel on May 3rd 2018.
- [Aurealis Therapeutics to present at the 11th Annual European Life Sciences CEO Forum & Exhibition](https://aurealistherapeutics.com/aurealis-news/aurealis-elsf2018/): Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki will attend and present the company's progress at the 11th Annual European Life Sciences CEO Forum & Exhibition in Zurich on February 26-27th 2018.
- [Aurealis Therapeutics to present at Swiss Nordic Bio 2018](https://aurealistherapeutics.com/aurealis-news/aurealis-swissnordicbio2018/): Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company's progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018.

## Pages
- [About](https://aurealistherapeutics.com/about/): Aurealis Therapeutics is a Swiss-Finnish clinical-stage company developing multi-target bacterial gene therapies using genetically engineered Lactcoccus cremoris. Advanced therapies from the company's modular platform produces multiple human therapeutic proteins simultaneously in the diseased tissue. In completed Phase 2 DIAMEND study, the lead product AUP-16 for chronic wounds (AUP-1602-C, Rememulgene arelactibac) showed tripled complete wound closure rate versus standard treatments in chronic non-healing Diabetic Foot Ulcers (nhDFUs).
- [Test table](https://aurealistherapeutics.com/test-table/): Chronic wounds · AUP-16
- [Aurealis Events](https://aurealistherapeutics.com/aurealis-events/): AllUpcoming EventsPast Events
- [Investors](https://aurealistherapeutics.com/investors/): CHRONIC WOUNDS, CANCER, INFLAMMATION AND BEYOND
- [Diabetic Foot Ulcers](https://aurealistherapeutics.com/diabetic-foot-ulcers/): Diabetic Foot Ulcers can heal with our multi-targeting product AUP-16
- [Work with us](https://aurealistherapeutics.com/work-with-us/): Join the Aurealis Therapeutics team
- [Cancer](https://aurealistherapeutics.com/cancer/): Cancers impact more than 20 million people each year and cause more than 10 million deaths.
- [Pipeline and Science](https://aurealistherapeutics.com/pipeline-and-science/): The full and up-to-date publication list is available at: aurealistherapeutics.com/pipeline-and-science/#publications.
- [Privacy Policy](https://aurealistherapeutics.com/privacy-policy/): We will retain your Personal Data only for as long as is necessary for the purposes set out in this Privacy Policy. We will retain and use your Personal Data to the extent necessary to comply with our legal obligations (for example, if we are required to retain your data to comply with applicable laws), resolve disputes, and enforce our legal agreements and policies.
- [Cookie Policy](https://aurealistherapeutics.com/cookie-policy/): This Cookie Policy explains what cookies are and how we use them, the types of cookies we use i.e, the information we collect using cookies and how that information is used, and how to control the cookie preferences. For further information on how we use, store, and keep your personal data secure, see our Privacy Policy.
- [Contact](https://aurealistherapeutics.com/contact/): CONTACT US DO YOU HAVE QUESTIONS OR SUGGESTIONS? We are happy
to HEAR FROM YOU! Contact us
- [Aurealis News](https://aurealistherapeutics.com/aurealis-news/): AllPress ReleasesNews
- [Partnering](https://aurealistherapeutics.com/partnering/): Aurealis Therapeutics is actively seeking strategic partners, licensees, and investors to bring its multi-target cell and gene therapies to patients worldwide. Opportunities span regional and global licensing of the lead product AUP-16 in chronic wounds, co-development and out-licensing of the oncology candidate AUP-55, and platform collaborations that apply Aurealis’ four-in-one technology to new indications across multi-factorial diseases such as chronic wounds, cancer, and inflammatory diseases. With positive Phase 2 diabetic foot ulcer data in hand, we are open to partnering discussions across territories.
- [Clinical Trials](https://aurealistherapeutics.com/clinical-trials/): More details about our Phase 1 Clinical Study:EU Clinical Trials Register
- [Chronic wounds](https://aurealistherapeutics.com/chronic-wounds/): WE HEAL CHRONIC WOUNDS WITH OUR MULTI-TARGET CELL AND GENE THERAPY PLATFORM
- [Home](https://aurealistherapeutics.com/): A game changer for chronic wounds, cancer and inflammatory diseases.

## Events
- [European Wound Management Association 2026 Conference](https://aurealistherapeutics.com/aurealis-events/ewma2026/): As Europe’s leading conference in wound management, EWMA brings together clinicians, researchers, and industry leaders to present the latest developments, exchange knowledge and advance standards of care. Aurealis’ participation in EWMA 2026 reflects its commitment to staying up to date with scientific and clinical developments while actively contributing to progress in the field.
- [Week of Strategic Meetings in China 2025](https://aurealistherapeutics.com/aurealis-events/strategicmeetingschina2025/): During the week of 20–25 October 2025, Aurealis Therapeutics’ CEO Juha Yrjänheikki and COO Laurent Décory traveled to Beijing, Shanghai and Hong Kong for a series of high-level meetings with key stakeholders, investors, and potential partners.
- [World Drug Safety Congress Europe 2025](https://aurealistherapeutics.com/aurealis-events/wdsceurope2025/): Aurealis Therapeutics Drug Safety Officer, Matleena Piiroinen, attended  the World Drug Safety Congress Europe 2025, that took place 7–8 October in Amsterdam, The Netherlands.
- [LSX World Congress USA 2025](https://aurealistherapeutics.com/aurealis-events/lsxworldcongressusa2025/): Aurealis Therapeutics attended LSX World Congress USA, 16-17 September 2025 in Boston. This was a leading forum that brought together innovators, investors, and senior life science dealmakers to shape the future of healthcare.
- [Biotech Week Boston 2025](https://aurealistherapeutics.com/aurealis-events/biotechweekboston2025/): Aurealis Therapeutics CEO, Juha Yrjänheikki, and COO, Laurent Décory, attended the Biotech Week Boston from 15-18 September 2025 in Boston, USA.
- [Partnering Week in China 2025](https://aurealistherapeutics.com/aurealis-events/partneringweekchina2025/): Aurealis Therapeutics team visited China from June 9–13, 2025, for a dedicated partnering week. Juha Yrjänheikki (CEO), Laurent Décory (COO), Hanna-Riikka Kärkkäinen (Director, Quality & Regulatory Affairs), and Jere Kurkipuro (Director, Pre-clinical & Pharmacology) met with investors, scientific partners, and licensing stakeholders to explore new collaboration opportunities.
- [Swiss Biotech Day 2025](https://aurealistherapeutics.com/aurealis-events/swissbiotechday2025/): A premier global biotechnology conference for life sciences professionals, held in Basel, Switzerland May 5-6, 2025. Laurent Décory (COO) attended the event and participated in the Microbiome Innovators session.
- [Symposium on Advanced Wound Care 2025](https://aurealistherapeutics.com/aurealis-events/sawc2025/): Symposium on Advanced Wound Care (SAWC) Spring, held April 30–May 4, 2025, in Grapevine, TX. Juha Yrjänheikki (CEO) and Laurent Décory (COO) participated to meet with Advanced Wound Care companies to discuss potential partnerships, as well as with clinicians and KOLs to discuss clinical plans.
- [Live Microbial Products Symposium 2025](https://aurealistherapeutics.com/aurealis-events/lmps2025/): Symposium on live biotherapeutic products, held in Amsterdam on April 29–30, 2025. Igor Mierau, Director of Genetic Engineering and Manufacturing, participated as a Key Speaker.

## Categories